Tofacitinib (Xeljanz) — Competitive Intelligence Brief

Tofacitinib (Xeljanz) (tofacitinib-xeljanz) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Janus Kinase Inhibitor. Area: Immunology.

marketed Janus Kinase Inhibitor JAK1 and JAK3 Immunology

Target snapshot

Tofacitinib (Xeljanz) (tofacitinib-xeljanz) — Pfizer.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tofacitinib (Xeljanz) TARGET	tofacitinib-xeljanz	Pfizer	marketed	Janus Kinase Inhibitor	JAK1 and JAK3
Cibinqo	Abrocitinib	Pfizer	marketed	Janus Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK1	2022-01-01
Cibinqo	abrocitinib	Pfizer	marketed	Janus Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK1	2022-01-01
ABROCITINIB	ABROCITINIB		marketed	Janus Kinase Inhibitor [EPC]	JAK1	2021-01-01
Olumiant	baricitinib	Eli Lilly	marketed	Janus Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK2	2018-01-01
BARICITINIB	BARICITINIB		marketed	Janus Kinase Inhibitor [EPC]		2017-01-01
In open-label phase: treatment with tofacitinib	in-open-label-phase-treatment-with-tofacitinib	Pfizer	marketed	Janus kinase inhibitor	Janus kinase 1 (JAK1), Janus kinase 3 (JAK3), and tyrosine kinase 2 (TYK2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Janus Kinase Inhibitor class)

1. Peking Union Medical College Hospital · 1 drug in this class
2. Pfizer · 1 drug in this class